PKI Share Price | Revvity, Inc. Stock Analysis & Recommendation

Q: How big is Revvity, Inc.?

Market Cap: As of Jun 18, Revvity, Inc. has a market capitalization of 11,098.61 million, categorizing it as a Mid Cap company.Recent Quarterly Performance: For the latest four quarters, Revvity, Inc. reported net sales of 2,769.86 million and a net profit of 296.05 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 7,666.87 million and total assets of 12,392.48 million.

Q: What does Revvity, Inc. do?

Overview:Revvity, Inc. is a provider of products, services, and solutions in the Pharmaceuticals & Biotechnology industry, operating within the mid-cap market.Financial Snapshot:Most recent Net Sales: 665 Million (Quarterly Results - Mar 2025)Most recent Net Profit: 42 Million (Quarterly Results - Mar 2025)Market-cap: USD 11,098.61 Million (Mid Cap)Key Metrics:P/E: 33.00Dividend Yield: 0.31%Debt Equity: 0.27Return on Equity: 4.30%Price to Book: 1.45Contact Details:Address: 155 Federal St Ste 700, BOSTON MA: 02110-1727Tel: 1 781 6635776Website: http://www.perkinelmer.com/

Q: Is Revvity, Inc. technically bullish or bearish?

As of 3 October 2025, the technical trend for Revvity, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD remains bearish. The Bollinger Bands indicate a mildly bullish stance on the weekly chart but are mildly bearish on the monthly. Daily moving averages are mildly bearish, and the KST shows bearish signals for both weekly and monthly periods. Dow Theory indicates no trend on the weekly and mildly bearish on the monthly. In terms of performance, Revvity has outperformed the S&P 500 over the past week and month, with returns of 10.90% and 7.78% respectively, but has significantly underperformed over longer periods, including a -16.33% return year-to-date compared to the S&P 500's 14.18%. Overall, the current technical stance is mildly bearish, with mixed signals across different time frames.

Q: Is Revvity, Inc. overvalued or undervalued?

As of 31 October 2025, the valuation grade for Revvity, Inc. has moved from attractive to very expensive, indicating a shift towards overvaluation. The company appears to be overvalued, with a P/E ratio of 33, an EV to EBITDA of 15.29, and a PEG ratio of 3.05, which are all higher than the industry average. In comparison, The Cooper Cos., Inc. has a P/E of 34.28 and an EV to EBITDA of 14.70, while Align Technology, Inc. shows a more favorable P/E of 20.46 and an EV to EBITDA of 11.41.Furthermore, Revvity's stock has underperformed relative to the S&P 500, with a year-to-date return of -17.85% compared to the S&P 500's 16.30%, and a three-year return of -28.07% versus the S&P 500's 76.66%. This significant underperformance reinforces the notion that the stock is overvalued in its current state.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

344.37 k

Shareholding (Dec 2025)

FII

25.23%

Held by 271 FIIs

DII

10.51%

Held by 80 DIIs

Promoter

0.03%

How big is Revvity, Inc.?

22-Jun-2025

As of Jun 18, Revvity, Inc. has a market capitalization of 11,098.61 million, with net sales of 2,769.86 million and a net profit of 296.05 million over the latest four quarters. The company reported shareholder's funds of 7,666.87 million and total assets of 12,392.48 million as of Dec 24.

View full answer

What does Revvity, Inc. do?

22-Jun-2025

Revvity, Inc. is a mid-cap provider of products and solutions in the Pharmaceuticals & Biotechnology industry, with recent net sales of $665 million and a net profit of $42 million. Key metrics include a P/E ratio of 33.00 and a market cap of approximately $11.1 billion.

View full answer

Who are in the management team of Revvity, Inc.?

22-Jun-2025

As of March 2022, the management team of Revvity, Inc. includes Mr. Alexandros Michas (Independent Non-Executive Chairman), Mr. Prahlad Singh (President and CEO), and several Independent Directors: Dr. Peter Barrett, Mr. Samuel Chapin, Dr. Sylvie Gregoire, and Mr. Michel Vounatsos. This team combines executive leadership with independent oversight for the company's governance and strategy.

View full answer

Is Revvity, Inc. technically bullish or bearish?

07-Oct-2025

As of October 3, 2025, Revvity, Inc. shows a mildly bearish trend with mixed technical signals, having outperformed the S&P 500 recently but underperformed year-to-date.

View full answer

Is Revvity, Inc. overvalued or undervalued?

05-Nov-2025

As of October 31, 2025, Revvity, Inc. is considered very expensive and overvalued with a P/E ratio of 33 and an EV to EBITDA of 15.29, significantly underperforming the S&P 500 with a year-to-date return of -17.85%.

View full answer

Compare Revvity, Inc. with Similar Stocks

The Cooper Cos., Inc.Waters Corp.Hologic, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Poor Management Efficiency with a low ROCE of 10.24%

The company has been able to generate a Return on Capital Employed (avg) of 10.24% signifying low profitability per unit of total capital (equity and debt)

Poor long term growth as Net Sales has grown by an annual rate of -1.23% and Operating profit at -2.67% over the last 5 years

Flat results in Jun 25

With ROCE of 4.39%, it has a very expensive valuation with a 1.33 Enterprise value to Capital Employed

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 9,668 Million (Small Cap)

P/E

34.00

Industry P/E

Dividend Yield

0.34%

Debt Equity

0.32

Return on Equity

3.89%

Price to Book

1.33

Revenue and Profits:

Net Sales:

772 Million

(Quarterly Results - Dec 2025)

Net Profit:

96 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-10.17%

6 Months

1.41%

1 Year

-22.72%

2 Years

-17.56%

3 Years

-31.41%

4 Years

-50.89%

5 Years

-31.34%

Revvity, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Revvity, Inc. Faces Valuation Shift Amid Declining Sales and Rising Costs

Revvity, Inc., a small-cap company in the Pharmaceuticals & Biotechnology sector, has recently experienced a change in its valuation grade. Key financial metrics reveal challenges, including a decline in net sales and operating profit, alongside rising raw material costs and a high debt-equity ratio, impacting its market position.

Read full news article

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-5.47%

EBIT Growth (5y)

-17.28%

EBIT to Interest (avg)

10.80

Debt to EBITDA (avg)

2.07

Net Debt to Equity (avg)

0.27

Sales to Capital Employed (avg)

0.25

Tax Ratio

11.35%

Dividend Payout Ratio

13.61%

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

10.24%

ROE (avg)

10.51%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.33

EV to EBIT

30.27

EV to EBITDA

14.95

EV to Capital Employed

1.25

EV to Sales

4.19

PEG Ratio

Dividend Yield

0.34%

ROCE (Latest)

4.14%

ROE (Latest)

3.89%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bearish

Dow Theory

No Trend

Mildly Bearish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 99 Schemes (64.22%)

Foreign Institutions

Held by 271 Foreign Institutions (25.23%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 10.47% vs -2.97% in Sep 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 102.97% vs -14.49% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "772.10",
          "val2": "698.90",
          "chgp": "10.47%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "248.70",
          "val2": "192.90",
          "chgp": "28.93%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "23.50",
          "val2": "22.80",
          "chgp": "3.07%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-41.80",
          "val2": "-13.60",
          "chgp": "-207.35%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "95.80",
          "val2": "47.20",
          "chgp": "102.97%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "188.60%",
          "val2": "130.00%",
          "chgp": "5.86%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 3.67% vs 0.16% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -15.26% vs 57.72% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,856.10",
          "val2": "2,755.00",
          "chgp": "3.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "833.10",
          "val2": "838.40",
          "chgp": "-0.63%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "92.20",
          "val2": "96.30",
          "chgp": "-4.26%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-82.60",
          "val2": "-55.80",
          "chgp": "-48.03%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "239.90",
          "val2": "283.10",
          "chgp": "-15.26%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "149.80%",
          "val2": "149.00%",
          "chgp": "0.08%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

772.10

698.90

10.47%

Operating Profit (PBDIT) excl Other Income

248.70

192.90

28.93%

Interest

23.50

22.80

3.07%

Exceptional Items

-41.80

-13.60

-207.35%

Consolidate Net Profit

95.80

47.20

102.97%

Operating Profit Margin (Excl OI)

188.60%

130.00%

5.86%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is 10.47% vs -2.97% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is 102.97% vs -14.49% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

2,856.10

2,755.00

3.67%

Operating Profit (PBDIT) excl Other Income

833.10

838.40

-0.63%

Interest

92.20

96.30

-4.26%

Exceptional Items

-82.60

-55.80

-48.03%

Consolidate Net Profit

239.90

283.10

-15.26%

Operating Profit Margin (Excl OI)

149.80%

149.00%

0.08%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 3.67% vs 0.16% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -15.26% vs 57.72% in Dec 2024

All Annual Results

Company CV

About Revvity, Inc.

Revvity, Inc.

Pharmaceuticals & Biotechnology

PerkinElmer Inc. is a provider of products, services and solutions for the diagnostics, life sciences and applied markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. Its Discovery & Analytical Solutions segment serves the life sciences and applied markets. Through the Diagnostics Segment, it offers instruments, reagents, assay platforms, and software to hospitals, medical labs, clinicians, and medical research professionals. It provides early detection for genetic disorders from pregnancy to early childhood, and infectious disease testing for the diagnostics market. It offers its product under various brands, BACS-on-Beads, BIOCHIPs, Bioo Scientific, BoBs, chemagic, FragilEase, Genoglyphix, GSP, PG-Seq, PG-Find, Protein Clear, ProteinEXact and QSight, Glutomatic, Honigs Regression, HyperDSC, Inframatic, LAMBDA, NexION, NEN, OneSource, Opera Phenix, Operetta CLS and OsteoSense.

Company Coordinates

Company Details

155 Federal St Ste 700 , BOSTON MA : 02110-1727

Tel: 1 781 6635776

http://www.perkinelmer.com/

Registrar Details